Novo Nordisk’s decision to concentrate approximately DKK 1 billion of restructuring costs in Q3 has created a clear runway for Q4 earnings. With those one-off charges behind it, management expects cost savings to directly accrue to the upcoming quarter, lowering the expense base and improving operating leverage. Analysts have revised forecasts to reflect the benefit of these savings, setting the stage for a potential earnings beat relative to current consensus, which assumes a more conservative margin profile given earlier guidance cuts.

In January 2026 Novo Nordisk introduced its FDA-approved oral formulation of Wegovy, targeting chronic weight management in patients who prefer a non-injectable option. The pill recorded over 18,000 prescriptions in its first week, tapping into an estimated addressable population of 85 million U.S. adults with obesity or overweight conditions. Distribution partnerships with major retail and pharmacy channels—including leading online and warehouse club outlets—have ensured ample supply during launch, with management reporting robust demand signals that exceed initial rollout objectives.

To support sustained product availability and margin expansion, Novo Nordisk is integrating Catalent’s fill-finish site in Bloomington, Indiana. Once operational by mid-2026, the facility will effectively double the company’s U.S. injectable drug capacity, easing prior bottlenecks for both Ozempic and Wegovy. This expansion is expected to yield incremental gross margin improvements of 100–150 basis points over the next two years by optimizing production costs and reducing third-party manufacturing premiums.